Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Slim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Francois Lefebvre, Mark Cameron, J. Kaewkungwal, P. Pitisuttithum, S. Nitayaphan, S. Rerks-Ngarm, Jerome H. Kim, Rasmi Thomas, Peter B. Gilbert, Georgia D. Tomaras, Richard A. Koup, Nelson L. Michael, M. Juliana McElrath, Raphael Gottardo, Rafick-Pierre Sékaly
Format: article
Langue:EN
Publié: Nature Portfolio 2019
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/39e0d85840e44cd7872a97b96a0ffad9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.

Documents similaires